Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, today announced that the first patient has been enrolled in its Phase 2 clinical trial evaluating the company’s investigational nano-amorphous mineral-based therapy in patients with Stage IV pancreatic cancer.
The study, approved by the Helsinki Committee of Shaare Zedek Medical Center and the Israel Ministry of Health, aims to investigate whether this therapy can extend the survival of these patients by time to progression (PFS), overall survival (OS), response rate (ORR), and change in quality of life using a dedicated questionnaire.
Data is expected in Q3 of 2026.
Dr Ofer Purim is director of the Gastrointestinal Tumors Service at Shaare Zedek Medical Center and the study’s lead investigator.
Purim said: “Given the urgent need for new therapeutic approaches in pancreatic cancer, we are proud to be leading this important study.
“Our goal is to investigate whether Amorphical’s nano-amorphous mineral-based therapy can extend patient survival and improve quality of life for those with this aggressive disease.”
Pancreatic cancer is one of the deadliest forms of cancer with an estimated 496,000 cases diagnosed globally each year.
With limited treatment options, the overall five-year survival rate is less than 13 per cent, dropping to just 3 per cent for Stage IV patients.
Tumour acidity is a hallmark of advanced pancreatic cancer and plays a central role in immune evasion, metastasis, and resistance to therapy.
Amorphical’s proprietary nano-amorphous mineral technology is designed to selectively buffer the tumour microenvironment, potentially restoring immune activity, reducing tumour aggressiveness, and enhancing responses to standard treatments.
This Phase 2 trial builds on Amorphical’s extensive preclinical research and early clinical data from other indications, which have demonstrated the technology’s ability to modulate pathological acidity – a key factor in tumour growth.
Eden Ben, CEO of Amorphical, said: “First patient enrolment in this trial marks an important milestone for Amorphical and for patients battling one of the toughest cancers.
“Our vision is to harness the unique properties of our nano-amorphous mineral technology to address the acidic tumor microenvironment, with the ultimate goal of extending life for patients with Stage IV pancreatic cancer. We are deeply grateful to the clinical teams and patients who are making this progress possible.”
